S07-1066

• UNSPSC Description:

  S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/s07-1066.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC(Cl)=CC(C2=CC=C(C3(C(O)=O)CC3)C=C2F)=C1

• Molecular Weight:

  325.16

• References & Citations:

  [1]He S, et al. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment. J Med Chem. 2023 Jul 6.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  876625-29-5